PR Stories
Alex’s Lemonade Stand: The Crazy 8 Initiative Topics & Teams
October 1, 2018
ALSF launched the Crazy 8 Initiative to detail roadmaps toward cures for specific, hard-to-treat childhood cancers. This collaborative effort kicked off in the fall of 2018 with a meeting that brought together more than 90 top scientists from around the world providing expertise in eight key areas of need.
YouTube: Children’s Cause, Challenges in Clinical Trial Design
September 18, 2018
CHILDHOOD CANCER HEARING LOSS AN EXTERNALLY-LED PATIENT-FOCUSED DRUG DEVELOPMENT WORKSHOP: CHEMOTHERAPY-INDUCED HEARING LOSS IN PEDIATRIC ONCOLOGY 3:25-3:35 Challenges in Clinical Trial Design in Chemotherapy-Induced Hearing Loss | Greg Aune, MD, PhD, Assistant Professor, UT Health San Antonio-Greehey Children’s Cancer Research Institute The half-day meeting follows the FDA model for externally-led PFDD meetings and will feature […]
FDA: The Voice of the Patient – Childhood Cancer Hearing Loss
September 13, 2018
Introduction: On September 13, 2018, four advocacy organizations – Children’s Cause for Cancer Advocacy, Children’s Brain Tumor Foundation, Mattie Miracle Cancer Foundation, and Momcology – hosted an Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting to share with senior officials at the U.S. Food and Drug Administration and other chemotherapy-induced pediatric hearing loss stakeholders (e.g. families, caregivers, […]
Childhood Cancer Hearing Loss PFDD Meeting (Full Program)
September 13, 2018
The pediatric patient population with chemotherapy-induced hearing loss represents a segment of the cancer survivor community with a severe burden of disease with a great unmet medical need. An externally-led, FDA-approved Patient-Focused Drug Development (PFDD) meeting on September 13, 2018, near Washington, DC will explore these issues in-depth. The half-day meeting follows the FDA model […]
UT Health SA Newsroom: CPRIT awards millions to UT Health San Antonio
August 18, 2018
Cancer prevention programs and initiatives to recruit faculty to UT Health San Antonio got a $3.5 million boost from the Cancer Prevention & Research Institute of Texas (CPRIT). The awards, announced Aug. 16, bringing total funding to UT Health San Antonio by CPRIT to about $74.6 million since the program began in 2008. The UT […]
UT Health SA Newsroom: UT Health San Antonio physician-researcher contributes to international screening guidelines for rare pediatric cancers
August 2, 2018
SAN ANTONIO (Aug. 2, 2017) ―Approximately 10 percent of childhood cancer can be attributed to genetics. While genomic analysis has been used for some time to identify the risk of inherited cancer in adults, scientists are now using genomic analysis to identify genetic risk factors and to diagnose cancer at an early age in children. […]
CRISPR – Journal: CRISPR-Based Editing Reveals Edge-Specific Effects in Biological Networks
August 1, 2018
Yi Li, Chance M. Nowak, Daniel Withers, Alexander Pertsemlidis, Leonidas Bleris Abstract Unraveling the properties of biological networks is central to understanding both normal and disease cellular phenotypes. Networks consist of functional elements (nodes) that form a variety of diverse connections (edges), with each node being a hub for multiple edges. Herein, in contrast to node-centric network perturbation […]
Cancer Letters: miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer
July 28, 2018
Xiaojie Yuab, Yiqiang Zhanga, Xiuye Maa, Alexander Pertsemlidisabc Abstract Microtubule-targeting agents (MTAs) are widely used for the treatment of non-small cell lung cancer (NSCLC). The response rate is only ∼25%, mainly attributable to drug resistance. To identify the determinants of resistance in NSCLC, we performed a high-throughput screen using a library of miRNA mimics. Here we report that […]
Cancer Letters: Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells
July 1, 2018
AlfeuZanotto-Filhoac SubapriyaRajamanickama EvaLoranca V. Pragathi Masamsettia AparnaGorthiab July CarolinaRomeroab SonalTonapiab Rosangela Mayer Gonçalvesc Robert L.Reddickd RaymondBenavidese JohnKuhnde YidongChenf Alexander J.R.Bishopab Abstract Molecularly targeted compounds are emerging as a strategy to improve classical chemotherapy. Herein, we describe that using a low dose of the multikinase inhibitor sorafenib improves cyclophosphamide antitumor activity by inhibiting angiogenesis, metastasis, and promoting tumor healing in MDA-MB231 xenografts and the 4T1-12B syngeneic breast […]